BUZZ-Apimeds Pharma jumps as FDA backs faster approval path for non-opioid pain drugs
Reuters
Sep 12, 2025
BUZZ-Apimeds Pharma jumps as FDA backs faster approval path for non-opioid pain drugs
** Shares of drug developer Apimeds Pharmaceuticals APUS.A rise 26.5% to $2.48 premarket
** Late on Thursday, co welcomed new FDA draft guidance on non-opioid pain therapies
** Co said the U.S. FDA's proposal could help move its lead non-opioid drug candidate, Apitox, more quickly through clinical trials and toward regulatory approval
** Apitox is being developed to treat chronic pain caused by osteoarthritis, a condition that leads to long-term joint damage and reduced mobility
** As of last close, stock down 11.8% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.